New combo aims to wipe out hidden myeloma cells after transplant
NCT ID NCT05091372
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests whether adding belantamab mafodotin to lenalidomide after a stem cell transplant can turn residual myeloma cells undetectable in patients with newly diagnosed multiple myeloma. About 94 adults who have already had a transplant will receive the combination therapy. The goal is to improve disease control and reduce the chance of relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77051, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outsmart resistant myeloma?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Could an ALS drug clear the fog of chemo brain?
- Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients
- Gene clues may unlock new treatments for bone marrow cancer
- New study monitors infection risks in blood cancer patients on bispecific antibodies